advantig-202: tislelizumab /- ociperlimab in recurrent/metastatic cervical cancer
Published 10 months ago • 77 plays • Length 3:48Download video MP4
Download video MP3
Similar videos
-
1:16
keynote 826: pembrolizumab chemo in patients with advanced cervical cancer
-
4:03
rationale-306: tislelizumab and chemotherapy in escc
-
1:30
dr. monk on bevacizumab in recurrent cervical cancer
-
7:53
pembrolizumab for persistent, recurrent, or metastatic cervical cancer
-
6:12
metastatic and recurrent cervical cancer treatment
-
2:26
keynote-826: pembrolizumab plus chemotherapy for patients with metastatic cervical cancer
-
10:07
gabriel hortobagyi:
-
1:59
pembrolizumab in the treatment of head and neck cancer: is there more to the story?
-
6:17
sara tolaney, sabcs 2022: adjuvant paclitaxel and trastuzumab for node-negative her2 breast cancer
-
7:58
introduction: antibody-based cancer immunotherapy
-
1:01
immunothearpy combo treating advanced cervical cancer | osuccc – james
-
6:38
pembrolizumab with chemotherapy as first line for metastatic cervical cancer
-
1:07
phase ii results for pembrolizumab monotherapy in metastatic tnbc
-
0:50
phase i study of tak-676 pembrolizumab following radiotherapy in late-line nsclc, tnbc and scchn
-
0:54
biosimilars: a promising new therapeutic option in cancer treatment
-
1:36
dr. seiwert on pembrolizumab in head and neck cancer
-
0:59
findings for cemiplimab in advanced or recurrent cervical cancer
-
2:33
concurrent immunotherapy in sclc